Skip to main content

Table 3 Univariable and multivariable Cox proportional hazard analysis of factors associated with progression free survival

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

  Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age   0.148   
  ≤ 65 1    
  > 65 0.735 (0.484–1.116)    
Sex   0.149   
 Male 0.797 (0.489–1.115)    
 Female 1    
ECOG PS   0.518   
 0 1    
  ≥ 1 1.139 (0.767–1.692)    
Charlson Commorbidity index   0.697   
 0 1    
  ≥ 1 1.084 (0.722–1.626)    
Chronic hepatitis B   0.155   
 No 1    
 Yes 1.497 (0.934–2.320)    
Chronic hepatitis C   0.612   
 No 1    
 Yes 1.297 (0.475–3.547)    
Liver cirrhosis   0.157   
 No 1    
 Yes 1.551 (0.844–2.851)    
Biliary drainage   0.184   
 No 1    
 Yes 0.593 (0.275–1.281)    
Tumor size   0.394   
  ≤ 7 cm 1    
  > 7 cm 0.838 (0.558, 1.258)    
Vascular invasion   0.379   
 No 1    
 Yes 0.830 (0.548, 1.257)    
Hilar invasion   0.181   
 No 1    
 Yes 0.610 (0.296, 1.258)    
Liver metastasis   0.472   
 No 1    
 Yes 1.157 (0.777–1.723)    
Extrahepatic organ metastasis   0.280   
 No 1    
 Yes 1.246 (0.836–1.856)    
Distant lymph node metastasis   0.001   0.001
 No 1   1  
 Yes 2.135 (1.361–3.348)   2.085 (1.329–3.272)  
Number of metastatic sites     
 0 1    
 1 2.567 (1.064–6.194) 0.036   
  ≥ 2 3.422 (1.467–7.985) 0.004   
Total bilirubin   0.336   
  ≤ 1.5 x ULN 1    
  > 1.5 x ULN 0.611 (0.224–1.666)    
Alkaline phosphatase   0.765   
  ≤ 1.5 x ULN 1    
  > 1.5 x ULN 1.066 (0.703–1.616)    
Albumin   0.050   
  < 3.5 g/dL 1.725 (1.001–2.975)    
  ≥ 3.5 g/dL 1    
CA 19–9   0.818   
  ≤ 37 U/mL 1    
  > 37 U/mL 0.955 (0.643–1.417)    
PLR   0.006   0.009
  ≤ 148 1   1  
  > 148 1.828 (1.193–2.800)   1.766 (1.155–2.703)  
NLR   0.030   
  ≤ 5 1    
  > 5 1.738 (1.056–2.859)    
LMR   0.087   
  < 3.5 1.538 (0.939–2.520)    
  ≥ 3.5 1    
AGR   0.368   
  < 1.2 1.200 (0.807–1.786)    
  ≥ 1.2 1    
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio